Ivarmacitinib is a selective Janus kinase (JAK) inhibitor developed as an orally active pharmaceutical compound. It has been investigated for the treatment of inflammatory and autoimmune disorders, including conditions involving abnormal JAK-mediated cytokine signaling.
Ivarmacitinib is designed to inhibit JAK1 and JAK3, two members of the Janus kinase family involved in signaling pathways for multiple cytokines. By inhibiting these kinases, Ivarmacitinib may reduce downstream signaling associated with inflammatory and immune responses.
Ivarmacitinib is identified by CAS Number 1333115-63-5. It has the molecular formula C20H22N6O2 and a molecular weight of 378.44 g/mol. It is a synthetic small-molecule kinase inhibitor and is generally supplied as a pharmaceutical research or active pharmaceutical ingredient material according to the applicable specification.
Ivarmacitinib is a heterocyclic compound containing nitrogen-rich aromatic rings and an amide functionality. Its physicochemical properties support oral administration in investigational pharmaceutical formulations.
Ivarmacitinib selectively inhibits Janus kinase signaling, with activity against JAK1 and JAK3. JAK proteins transmit signals from several cytokine receptors to intracellular STAT proteins. Inhibition of JAK1/JAK3 can interfere with cytokine-mediated signaling and consequently modulate inflammatory and immune responses.
Ivarmacitinib has been investigated as a potential treatment for inflammatory and autoimmune diseases. Clinical development has included evaluation in conditions involving immune-mediated inflammation. Its development status and approved indications should be evaluated according to the applicable regulatory jurisdiction and current product documentation.
Pharmaceutical Ivarmacitinib can be characterized using validated chromatographic and spectroscopic analytical methods. HPLC may be used for assay and related-substance determination, while suitable spectroscopic and chromatographic techniques may be used for identity testing.
Quality control of Ivarmacitinib should include identity, assay, related substances, water content, residual solvents, elemental impurities and other applicable parameters according to the approved drug-substance specification.
Ivarmacitinib should be stored in a tightly closed container under controlled pharmaceutical storage conditions. The material should be protected from excessive heat, moisture, direct light and contamination. Specific storage requirements should follow the applicable manufacturer specification and Certificate of Analysis.
Ivarmacitinib may be supplied for pharmaceutical research, formulation development, analytical testing and other qualified applications, subject to applicable regulatory requirements. Product specifications, Certificate of Analysis, packaging configuration and regulatory documentation should be confirmed according to the intended application.
For Ivarmacitinib requirements, customers can request product specifications, analytical documentation, Certificate of Analysis, packaging information and commercial details. Quality parameters should be evaluated against the applicable pharmaceutical specification before procurement.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| pH (1% Solution) | 5.0 – 7.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | ≤ 1.5% |
| Melting Point | Approximately 235–240°C |